Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee

Starting soon · Phase 2 · Has a placebo group

Conditions studied: Osteoarthritis of the Knees

In brief

The purpose of this study is to determine the optimal dose of AD-211 in patients with osteoarthritis of the knee.

Key facts

Study ID

NCT07550231

Run by

Addpharma Inc.

People needed

200

Starts

2026-06-01

Expected to finish

2027-03-01

Last updated by the study team

2026-04-24

Who can join

Age: 19 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed informed consent
• Patients with osteoarthritis of the Knee
• Other inclusions applied

You may not qualify if…

• Patients with secondary osteoarthritis of the knee
• Other exclusions applied

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.